This has led to multiple studies exploring other strategies to reverse CD8+ T cell dysfunction [16], such as combination therapy with IFN‐triggering drugs and anti‐PD‐1/PD‐L1 agents or stimulation of CLL via CD40, which can reduce CD24 and CD52 expression on CD8+ T cells and restore their functionality [17]. Here, PDCD1 is linked to B-cell chronic lymphocytic leukemia.